Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer:
A Case Report and Literature Review / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 717-720, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-1010079
ABSTRACT
Immune checkpoint inhibitors (ICIs) show unique advantages in the treatment of lung cancer, making the treatment of lung cancer enter the era of immunotherapy, but ICIs will also have adverse reactions, and the incidence of immune-induced hematological toxicity is not very high. Immunotherapy-induced thrombocytopenia is a rare adverse event.We report one case of thrombocytopenia induced by ICIs and review the literature on thrombocytopenia associated with ICIs and discuss the clinical features, possible mechanisms, and optimal treatment.
.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Trombocitopenia
/
Púrpura Trombocitopénica Idiopática
/
Anticuerpos Monoclonales Humanizados
/
Neoplasias Pulmonares
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS